Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Evaxion Biotech ( (EVAX) ) has shared an announcement.
Evaxion Biotech A/S announced amendments to its Articles of Association following a capital increase, effective January 7 and January 15, 2025, through the exercise of pre-funded warrants. Additionally, an Extraordinary General Meeting held on January 17, 2025, resulted in resolutions to reduce the company’s share capital to cover losses, affecting the nominal value of shares and ensuring equitable shareholder treatment.
More about Evaxion Biotech
Evaxion Biotech A/S is a Danish company specializing in creating advanced software for the development of novel immune therapies and vaccines.
YTD Price Performance: -26.88%
Average Trading Volume: 85,727
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.63M
Find detailed analytics on EVAX stock on TipRanks’ Stock Analysis page.
